(MENAFN- PR Newswire) MONTREAL, March 27, 2024 /PRNewswire/ -- Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function, announced today that it will participate in the following investor conferences:
23rd Annual Needham Virtual Healthcare Conference, being held in a virtual format April 8-11, 2024. Clarissa Desjardins, Ph.D., CEO of Congruence, will present a company overview on Tuesday, April 9th at 9:30 am ET. Company management will also participate in one-on-one meetings with investors at this conference. 2024 Bloom Burton & Co. Healthcare Investor Conference, being held April 16-17, 2024, in Toronto, Ontario. Dr. Desjardins will present a company overview on Tuesday, April 16 at 1:30 pm ET. Company management will also participate in one-on-one meetings with investors at this conference.
About Congruence Therapeutics
Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, RevenirTM, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter.
For more information, please visit
.
Company Contact
Charles
Grubsztajn
Chief Operating Officer
[email protected]
Media Contact
Amy Conrad
Juniper Point
[email protected]
858-366-3243
SOURCE Congruence Therapeutics
MENAFN27032024003732001241ID1108029883
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.